| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Atea Pharmaceuticals, Inc. (AVIR) has 7 insiders with recent SEC Form 4 filings, including 2 buys and 11 sells. AVIR is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 506.5K | $2.81M | - | |
| Dir | 164.8K | $913.0K | - | |
| Dir | 112.8K | $624.6K | - | |
| Dir | 95.2K | $527.4K | - | |
| Dir | 86.0K | $476.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2025 | Berger Franklin M52 | Director | Buy | 25,000 | $3.26 | $81,498.50 | +2.7% | -9.9% | +2.1% | |
| Dec 10, 2024 | Berger Franklin M52 | Director | Sell | 359,606 | $2.85 | $1,023,474.64 | -44.3% | -0.7% | +7.5% | |
| Sep 19, 2024 | Sommadossi Jean-Pierre73 | President, CEO, And Chairman | Sell | 57,969 | $4.04 | $234,155.07 | -0.3% | -17.3% | -24.6% | |
| Jun 20, 2024 | Polsky Bruce | Director | Sell | 17,544 | $3.49 | $61,144.35 | -21.1% | +16.7% | -5.0% | |
| Jun 5, 2024 | Sommadossi Jean-Pierre73 | President, CEO, And Chairman | Sell | 1,006 | $4.00 | $4,024.00 | - | -8.3% | -19.4% | |
| Feb 1, 2024 | Corcoran Andrea | See Remarks | Sale+OE | 15,843 | $3.84 | $60,914.75 | -2.3% | -8.8% | -27.5% | |
| Feb 1, 2024 | Sommadossi Jean-Pierre73 | President, CEO, And Chairman | Sale+OE | 56,910 | $3.85 | $218,818.95 | -32.8% | -8.8% | -27.5% | |
| Feb 1, 2024 | Horga Maria Arantxa | Chief Medical Officer | Sale+OE | 15,870 | $3.84 | $60,963.02 | -38.2% | -8.8% | -27.5% | |
| Feb 1, 2024 | Foster Wayne | EVP, Chief Accounting Officer | Sale+OE | 12,477 | $3.84 | $47,904.19 | -37.4% | -8.8% | -27.5% | |
| Feb 1, 2024 | Vavricka John | Chief Commercial Officer | Sale+OE | 11,819 | $3.84 | $45,420.42 | -35.5% | -8.8% | -27.5% |